Literature DB >> 16198987

Treatment of relapsed blast-phase Philadelphia-chromosome-positive leukaemia after non-myeloablative stem-cell transplantation with donor lymphocytes and imatinib.

Bipin N Savani1, Ramaprasad Srinivasan, Igor Espinoza-Delgado, Colleen Dorrance, Yoshiyuki Takahashi, Takehito Igarashi, Katayoun Rezvani, Andreas Lundqvist, A John Barrett, Richard W Childs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16198987     DOI： 10.1016/S1470-2045(05)70391-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

1.  Presence of CD34(+)CD38(-)CD58(-) leukemia-propagating cells at diagnosis identifies patients at high risk of relapse with Ph chromosome-positive ALL after allo-hematopoietic SCT.

Authors:  Y Kong; L-P Xu; Y-R Liu; Y-Z Qin; Y-Q Sun; Y Wang; H Jiang; Q Jiang; H Chen; Y-J Chang; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-12-08       Impact factor: 5.483

2.  Case of a patient with Philadelphia-chromosome-positive acute lymphoblastic leukemia relapsed after myeloablative allogeneic hematopoietic stem cell transplantation treated successfully with imatinib and sequential donor lymphocyte infusions.

Authors:  Makoto Yoshimitsu; Hiroshi Fujiwara; Atsuo Ozaki; Heiichiro Hamada; Kakushi Matsushita; Naomichi Arima; Chuwa Tei
Journal:  Int J Hematol       Date:  2008-08-12       Impact factor: 2.490

3.  Long-term persistence of nonpathogenic clonal chromosome abnormalities in donor hematopoietic cells after allogeneic stem cell transplantation.

Authors:  Gulsun Erdag; Jeanne M Meck; Aurelia Meloni-Ehrig; Ludmila Matyakhina; Theresa Donohue; Ramaprasad Srinivasan; Philip Mowrey; JoAnn Kelly; Aleah Smith; Richard Childs
Journal:  Cancer Genet Cytogenet       Date:  2009-04-15

4.  High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.

Authors:  Agnes S M Yong; Katayoun Rezvani; Bipin N Savani; Rhoda Eniafe; Stephan Mielke; John M Goldman; A John Barrett
Journal:  Blood       Date:  2007-04-05       Impact factor: 22.113
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.